Last reviewed · How we verify
RSV-F Vaccine
RSV-F Vaccine is a Recombinant protein vaccine Biologic drug developed by Novavax. It is currently in Phase 3 development for Prevention of respiratory syncytial virus (RSV) infection in older adults (≥60 years), Prevention of RSV disease in infants (via maternal immunization).
RSV-F Vaccine stimulates the immune system to produce antibodies and cellular immunity against the respiratory syncytial virus fusion (F) protein, preventing RSV infection.
RSV-F Vaccine stimulates the immune system to produce antibodies and cellular immunity against the respiratory syncytial virus fusion (F) protein, preventing RSV infection. Used for Prevention of respiratory syncytial virus (RSV) infection in older adults (≥60 years), Prevention of RSV disease in infants (via maternal immunization).
At a glance
| Generic name | RSV-F Vaccine |
|---|---|
| Sponsor | Novavax |
| Drug class | Recombinant protein vaccine |
| Target | RSV fusion (F) protein |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine uses a recombinant RSV fusion protein formulated with Novavax's Matrix-M adjuvant to elicit both humoral and cell-mediated immune responses. By targeting the F protein, a key surface antigen of RSV, the vaccine aims to prevent viral attachment and entry into respiratory epithelial cells, thereby reducing infection risk and disease severity.
Approved indications
- Prevention of respiratory syncytial virus (RSV) infection in older adults (≥60 years)
- Prevention of RSV disease in infants (via maternal immunization)
Common side effects
- Injection site pain
- Injection site erythema
- Myalgia
- Fatigue
- Headache
Key clinical trials
- The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products (PHASE4)
- Safety, Tolerability and Immunogenicity of a Maternal Respiratory Syncytial Virus (RSV) Vaccine (MKK900) in Healthy Adult Women (PHASE1)
- Structured Review: To Optimise Management and Prevent Harm in COPD (NA)
- TARSILA Real-World Evidence Study
- A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Older Adults in Korea (PHASE3)
- Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults. (PHASE3)
- Systems Biological Analysis of Immune Responses to RSV Vaccine (PHASE4)
- RSV Vaccine Response in Stem Cell and CAR-T Therapy Recipients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RSV-F Vaccine CI brief — competitive landscape report
- RSV-F Vaccine updates RSS · CI watch RSS
- Novavax portfolio CI
Frequently asked questions about RSV-F Vaccine
What is RSV-F Vaccine?
How does RSV-F Vaccine work?
What is RSV-F Vaccine used for?
Who makes RSV-F Vaccine?
What drug class is RSV-F Vaccine in?
What development phase is RSV-F Vaccine in?
What are the side effects of RSV-F Vaccine?
What does RSV-F Vaccine target?
Related
- Drug class: All Recombinant protein vaccine drugs
- Target: All drugs targeting RSV fusion (F) protein
- Manufacturer: Novavax — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Prevention of respiratory syncytial virus (RSV) infection in older adults (≥60 years)
- Indication: Drugs for Prevention of RSV disease in infants (via maternal immunization)
- Compare: RSV-F Vaccine vs similar drugs
- Pricing: RSV-F Vaccine cost, discount & access